{{Drugbox
| drug_name         = 特力利汀<br>Teneligliptin
| IUPAC_name        = {(2''S'',4''S'')-4-[4-(3-Methyl-1-phenyl-1''H''-pyrazol-5-yl)-1-piperazinyl]-2-pyrrolidinyl}(1,3-thiazolidin-3-yl)methanone
| image             = Teneligliptin.svg
| alt               = 
| caption           = 
<!-- Clinical data -->
| tradename         = 「Tenelia」 
| Drugs.com         = 
| MedlinePlus       = 
| pregnancy_AU      = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US      = <!-- A / B            / C / D / X -->
| pregnancy_category= 
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status      = 在日本通過審批
| routes_of_administration = 

<!-- Pharmacokinetic data -->
| bioavailability   = 
| protein_bound     = 
| metabolism        = 
| elimination_half-life = 
| excretion         = 

<!-- Identifiers -->
| CAS_number        = 760937-92-6
| CAS_number_Ref    = {{cascite|changed|??}}
| ATCvet            = 
| ATC_prefix        = <!-- 'none' if uncategorised -->
| ATC_suffix        = 
| PubChem           = 11949652
| DrugBank          = 
| ChemSpiderID      =

<!-- Chemical data -->
| C=22 | H=30 | N=6 | O=1 | S=1
| molecular_weight  = 426.58 g/mol
| smiles = CC1=NN(C(=C1)N2CCN(CC2)[C@H]3C[C@H](NC3)C(=O)N4CCSC4)C5=CC=CC=C5
| StdInChI=1S/C22H30N6OS/c1-17-13-21(28(24-17)18-5-3-2-4-6-18)26-9-7-25(8-10-26)19-14-20(23-15-19)22(29)27-11-12-30-16-27/h2-6,13,19-20,23H,7-12,14-16H2,1H3/t19-,20-/m0/s1
| StdInChIKey=WGRQANOPCQRCME-PMACEKPBSA-N
}}
{{medical}}
特力利汀（[[國際非專利藥品名稱|國際非專利藥品名稱]]：Teneligliptin，商品名爲「'''Tenelia'''」），係治療[[2型糖尿病|2型糖尿病]]的藥物。目前，該藥已在日本通過相關審批 <ref>{{cite journal | journal = Annual Reports in Medicinal Chemistry | volume = 48 | pages = 523–524 | title = Teneligliptin (Antidiabetic) | chapter = To Market, To Market - 2012 | author = Joanne Bronson, Amelia Black, T. G. Murali Dhar, Bruce A. Ellsworth, and J. Robert Merritt | doi=10.1016/b978-0-12-417150-3.00028-4}}</ref>  It belongs to the class of anti-diabetic drugs known as [[dipeptidyl_peptidase-4_inhibitor|dipeptidyl peptidase-4 inhibitor]]s or "gliptins".<ref>{{cite journal | pmid = 23671395 | year = 2013 | last1 = Kishimoto | first1 = M | title = Teneligliptin: A DPP-4 inhibitor for the treatment of type 2 diabetes | volume = 6 | pages = 187–95 | doi = 10.2147/DMSO.S35682 | pmc = 3650886 | journal = Diabetes, metabolic syndrome and obesity : targets and therapy}}</ref>

==參考==
{{reflist}}

{{Oral hypoglycemics and insulin_analogs}}
{{gastrointestinal-drug-stub}}

[[分類:糖尿病藥物|分類:糖尿病藥物]]